F8 and hemophilia A: These positive outcomes confirm previously reported results of a phase‐1 clinical trial [15], and are consistent with a series of HAVEN studies carried out among children, adults, and adolescents with hemophilia A. In the HAVEN 1 study, weekly emicizumab was well tolerated and linked to low rate of ABR in adults and adolescents (ABR: 2.9) with hemophilia A and FVIII inhibitors, and a significant number of participants experienced zero treated bleeds [63%].